Thank you for the list of trial sites. While I

Thank you for the list of trial sites.

While I can't count or read, I was able to do some basic math on the number of clinics participating in each trial by assigning each a number of ounces (of filet mignon, of course) and then divided by how many I'd typically eat at one meal (two, of course). Then I converted each of those calculations into volume so I could run a final wine-based analysis.

All in all, it looks like we have something like 25 clinics participating in each trial, which is outstanding.

You may remember that we had 18 involved with CD12, and I'd argue that many didn't enroll more than a couple patients because we weren't known, nor were we even near the front of the lineup of trials these sites were focused on enrolling.

In Brazil we have a very eager partner with many more facilities. Who, coincidentally, has offered (and been paid) to move us to the front of the line to expedite enrollment.

With that many clinics aggressively enrolling patients, the proper dosing regimen that's built into these trials, far less chance of a randomization-based disaster due to trial design, and everything we know about the science of Leronlimab, I feel pretty damn good right about now.

The potential of Leronlimab is immense, and for the first time in a while we're finally back to being on the cusp of that potential making itself known to the world. Once the cat's out of the bag there'll be no stopping it. Or our share price.

And welcome back, TonyCorvette. I'm ready and haven't missed anything. Glad you're alive??? (Still not sure if you're a robot or not)